Welcome to our dedicated page for Oncotelic Therapeutics news (Ticker: OTLC), a resource for investors and traders seeking the latest updates and insights on Oncotelic Therapeutics stock.
Oncotelic Therapeutics, Inc. reports developments as a clinical-stage biopharmaceutical company focused on oncology, immunotherapy and rare-disease therapeutics. Company updates cover its internal drug pipeline, orphan oncology programs, antisense and small molecule injectable drug candidates, and partnerships or joint ventures used to license and co-develop selected candidates.
Recurring OTLC news also includes the PDAOAI AI platform for research, biomarker discovery, regulatory processes and GMP-compliant robotics, the company's 45% interest in GMP Bio and related Sapu Bio and Sapu Nano programs, and completed portfolio actions such as field-specific monetization of N2B nose-to-brain delivery assets.
Oncotelic (OTC:OTLC) will showcase its PDAOAI™ drug discovery platform in the Product & Engineering keynote at Qdrant Vector Space Day 2026 on June 11 in San Francisco.
According to Oncotelic, PDAOAI indexes about 28 million PubMed abstracts on Qdrant and incorporates novel manifold folding and shell sampling techniques to enhance biomedical knowledge retrieval and reduce LLM hallucinations.
The company reports compressing development of SAPU 003 and SAPU 006 from concept to IND within 24 months, including GMP manufacturing build-out and first-in-human clinical material shipment.
Oncotelic Therapeutics (OTCQB: OTLC) was featured in a BioMedWire editorial highlighting nanotechnology-based oncology drug delivery. The company is developing Sapu003 and its Deciparticle platform, focusing on nanotech-driven delivery systems and pharmacokinetic optimization to enhance existing cancer therapies rather than discovering entirely new compounds.
Oncotelic Therapeutics (OTCQB:OTLC) and Sapu Nano are expanding the Phase 1b Sapu003 (Everolimus for Injection) program and have appointed Global Clinical Trials (GCT) as lead CRO for multinational Study SP-03-B101.
The move extends development beyond Australia into Europe, builds global clinical infrastructure, and supports future Phase 3 and registrational plans using the Deciparticle™ nanomedicine platform.
Oncotelic Therapeutics (OTCQB: OTLC) was featured in a BioMedWire editorial highlighting industry efforts to enhance existing cancer therapies through advanced drug delivery.
The company is progressing its Sapu003 program and Deciparticle(TM) platform, targeting scalable nanotechnology-enabled delivery and AI-enhanced biomedical infrastructure for oncology and rare disease applications.
Oncotelic Therapeutics (OTCQX:OTLC) and Sapu Nano will present the Deciparticle™ nanomedicine platform at BIO International Convention 2026 in San Diego.
The company will showcase ultra-small intravenous nanomedicine formulations, AI-enabled oncology development via PDAOAI™, and progress in programs including Sapu006 and Sapu003.
Oncotelic Therapeutics (OTCQB: OTLC) filed first quarter 2026 results and outlined strategic progress in oncology, AI-enabled development, and drug delivery platforms. The company continued advancing Sapu Nano deciparticle oncology programs, AI tools, a nose-to-brain CNS platform, and GMP Bio manufacturing infrastructure.
Oncotelic maintained the fair value of its 45% GMP Biotechnology stake at approximately $388 million as of March 31, 2026, supported by an independent ASC 820 valuation. Management reported no material events requiring a change in this valuation framework.
Oncotelic Therapeutics (OTCQB: OTLC) announced inclusion in a BioMedWire editorial focused on CNS drug-delivery technologies. The piece highlights the challenge of the blood-brain barrier and rising needs in Alzheimer’s and biodefense.
Oncotelic’s proprietary intranasal nose-to-brain (N2B) platform is described as rapidly shuttling therapeutics directly to the brain.
Sapu Nano and Oncotelic (OTCQB: OTLC) announced dosing of the first patient in a Phase 1b trial of Sapu003, an intravenous Deciparticle™ formulation of everolimus, for advanced mTOR-sensitive solid tumors.
The open-label, dose-escalation study evaluates safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity across two cohorts, with weekly IV dosing and multiple planned dose levels.
Oncotelic Therapeutics (OTCQB: OTLC) announced its inclusion in a BioMedWire editorial highlighting advances in CNS drug delivery. The company is developing a proprietary intranasal nose-to-brain (N2B) system aimed at bypassing the blood-brain barrier to enable rapid, targeted therapeutic delivery to the brain.
Oncotelic Therapeutics (OTCQB: OTLC) closed a strategic asset transfer with Lunai Bioworks (LNAI) on May 6, 2026, granting Lunai worldwide rights to Oncotelic’s N2B intranasal delivery system IP for biodefense and Alzheimer’s disease fields.
In return, Oncotelic received $12.5 million in Lunai Series B Convertible Preferred Stock and will retain N2B rights outside those fields (e.g., Parkinson’s, sexual dysfunction). The deal aims to accelerate CNS biodefense and AD development and position Oncotelic for government funding opportunities.